GlassScriptPhysician profile
Jill T Proctor
NPI 1639250624
$7,768.88
in general payments reported to CMS, 2019-2025
25 companies · $1,889 in 2025
The $1,889 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $756 · 2022: $1,576 · 2023: $1,936 · 2024: $1,611 · 2025: $1,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,865 · Education: $572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,864.58 |
| Education | $572.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,430.81 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,038.94 | 2021-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $886.49 | 2021-2025 | |
| Janssen Biotech, INC. | $782.72 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $769.97 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $535.98 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $523.53 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $458.74 | 2022-2025 | Sotyktu |
| Pfizer INC. | $286.76 | 2021-2025 | |
| Ucb, INC. | $286.30 | 2021-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $231.87 | 2022-2025 | Nemluvio, Aklief, Oracea |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $130.75 | 2022-2025 | Jublia, Arazlo, Duobrii |
| Mayne Pharma Commercial LLC | $87.67 | 2025 | |
| Incyte Corporation | $78.84 | 2023-2025 | Opzelura |
| Journey Medical Corporation | $37.78 | 2022-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $35.24 | 2025 | Zoryve |
| Botanix Sb INC | $33.06 | 2025 | Sofdra |
| Lnhc, INC | $22.54 | 2025 | Zelsuvmi |
| Biofrontera INC. | $20.77 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $19.38 | 2025 | Breztri |
| Leo Pharma INC. | $18.42 | 2025 | Anzupgo |
| Verrica Pharmaceuticals INC. | $16.13 | 2023 | Ycanth |
| Novo Nordisk INC | $15.45 | 2021 | |
| Dermavant Sciences, INC. | $14.78 | 2024 | Vtama |
| Organon LLC | $5.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Proctor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.